<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1255">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03090542</url>
  </required_header>
  <id_info>
    <org_study_id>GLOCK-Pilot 2017</org_study_id>
    <nct_id>NCT03090542</nct_id>
  </id_info>
  <brief_title>GPur- Luminating Oral Cholesterol Kinetics Pilot Study</brief_title>
  <acronym>GLOCK-pilot</acronym>
  <official_title>39 Day Randomized, Open Label, Two Arm Cross Over Study of Clinoptilolite (Gpur) in Healthy Adult Subjects Not Requiring or Receiving Lipid Lowering Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Collaborative Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glock Health, Science and Research, Gmbh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Collaborative Research Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In healthy subjects not receiving or requiring lipid lowering therapy and who do not have
      diabetes, the use of clinoptilolite (GPUR) will result in a reduction of absorbed dietary
      cholesterol observed over 6 days of therapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2017</start_date>
  <completion_date type="Anticipated">December 15, 2017</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in fractional cholesterol absorption in human subjects taking clinoptilolite over 6 days</measure>
    <time_frame>39 days</time_frame>
    <description>Primary Objective</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline by gender to determine gender difference in fractional cholesterol absorption rates</measure>
    <time_frame>39 days</time_frame>
    <description>Secondary Objective</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to end of treatment to evaluate for safety changes in metabolic profile measurements</measure>
    <time_frame>39 days</time_frame>
    <description>Secondary Objective</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Cholesterol Absorption</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>clinoptilolite</intervention_name>
    <description>randomized, open-label, cross-over study of control vs clinoptilolite with a washout period separating the 2 phases</description>
    <arm_group_label>Product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults over 18 years of age

          -  Not receiving or requiring lipid lowering therapy

          -  Willingness to give informed consent

          -  Able to keep a dietary log

          -  Willing to maintain a consistent day to day routine during the study (no major
             changes in lifestyle, exercise, food pattern, smoking habits, etc)

        Exclusion Criteria:

          -  Current use of oral lipid binding agents (colesevelam, cholestyramine, ezetimibe)
             fibrates, niacin or statins

          -  Current use of dietary supplements enriched with fat soluble vitamins,
             mono/polyunsaturated fat (fish-oil etc.) or probiotics

          -  Any oral antibiotic use, currently or within the past 14 days

          -  Diabetes, Type I and Type II

          -  Currently following a restrictive diet

          -  GI motility disorders (irritable bowel syndrome, diabetic gastroparesis, etc)

          -  Prior gastric or bowel resection

          -  Inflammatory bowel disease (Crohns, ulcerative colitis, diverticulitis, celiac sprue,
             etc)

          -  Co-morbidities with anticipated life expectancy &lt; 12 months

          -  ESRD on dialysis

          -  Known intolerance to silicium or aluminum compounds

          -  Excess alcohol consumption (&gt;1 drink per day)

          -  Pregnancy, nursing or not taking/using contraception

          -  Hepatobiliary disorders or renal disease

          -  Plasma total cholesterol &gt; 240mg/dl or Triglycerides &gt; 265.5 mg/dl

          -  No plant-sterol enriched food products allowed in diet &amp; supplements

          -  BMI &gt; 35
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Narendra Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Canadian Collaborative Research Network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Tsigoulis</last_name>
    <phone>9054538885</phone>
    <phone_ext>428</phone_ext>
    <email>mtsigoulis@ccrnmd.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahesh Kajil</last_name>
    <phone>9054538885</phone>
    <phone_ext>414</phone_ext>
    <email>mkajil@ccrnmd.com</email>
  </overall_contact_backup>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 20, 2017</lastchanged_date>
  <firstreceived_date>March 6, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
